The U.S. Court of Appeals for the Fourth Circuit on Thursday reversed a $1.25 million jury verdict awarded to the family of a deceased woman who claimed she suffered gastrointestinal bleeding as a result of taking the blood thinner Pradaxa.
The circuit’s reversal of the verdict was a win for defendant Boehringer Ingelheim Pharmaceuticals, which argued that federal law preempted plaintiff Betty Knight’s state law claims that Boehringer failed to adequately warn about the risks of taking Pradaxa.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]